GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Cash Ratio

Opus Genetics (STU:R3X1) Cash Ratio : 6.02 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Opus Genetics's Cash Ratio for the quarter that ended in Sep. 2024 was 6.02.

Opus Genetics has a Cash Ratio of 6.02. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Opus Genetics's Cash Ratio or its related term are showing as below:

STU:R3X1' s Cash Ratio Range Over the Past 10 Years
Min: 0.16   Med: 6.94   Max: 15.5
Current: 6.02

During the past 5 years, Opus Genetics's highest Cash Ratio was 15.50. The lowest was 0.16. And the median was 6.94.

STU:R3X1's Cash Ratio is ranked better than
72.24% of 1470 companies
in the Biotechnology industry
Industry Median: 2.69 vs STU:R3X1: 6.02

Opus Genetics Cash Ratio Historical Data

The historical data trend for Opus Genetics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Cash Ratio Chart

Opus Genetics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
0.16 5.15 6.42 15.50 12.50

Opus Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.84 12.50 8.15 9.87 6.02

Competitive Comparison of Opus Genetics's Cash Ratio

For the Biotechnology subindustry, Opus Genetics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opus Genetics's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Cash Ratio falls into.


';

Opus Genetics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Opus Genetics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=46.323/3.707
=12.50

Opus Genetics's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=33.008/5.486
=6.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opus Genetics  (STU:R3X1) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Opus Genetics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Opus Genetics Business Description

Traded in Other Exchanges
Address
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines